iShares MSCI Taiwan ETF vs McKesson Corporation — how do they compare? iShares MSCI Taiwan ETF trades at $105.6, while McKesson Corporation trades at $898 (market cap $105.14B). The key difference: McKesson Corporation pays a 0.42% dividend while iShares MSCI Taiwan ETF pays none, and iShares MSCI Taiwan ETF is trading nearer its 52-week high, McKesson Corporation nearer its low. Which is the better fit depends on your goals.
| EWT | MCK | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $111.53 | $995.69 |
52-Week Low | $58.05 | $659.01 |
Market Cap | — | $105.14B |
Enterprise Value | — | $111.67B |
Dividend Yield | — | 0.42% |
Signals from Pluang's Aura AI — not financial advice
EWT, the iShares MSCI Taiwan ETF, trades at $103.09, up 1.09% today, with a bullish technical signal driven by strong moving average alignment. Recent news highlights Taiwan's market outperformance, fueled by AI-driven semiconductor demand, with the ETF gaining over 60% year-to-date. Key support lies at $102, while resistance is at $104. The RSI_6 at 96.58 indicates overbought conditions, suggesting potential near-term consolidation.
The outlook remains positive due to Taiwan's critical role in the global semiconductor supply chain, though risks include geopolitical tensions with China and dependency on AI sector momentum. Analysts are bullish given the ETF's exposure to top performers like TSMC, but investors should monitor any shifts in foreign capital flows and semiconductor cycle dynamics.
No Aura AI signal available yet.
Trailing returns across standard periods
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →